Product Code: GVR-4-68039-985-7
AI In Oncology Market Summary
The global AI in oncology market size was estimated at USD 6.00 billion in 2025 and is expected to reach USD 38.91 billion by 2033, growing at a CAGR of 24.77% from 2026 to 2033. The growth of the market is attributed to increasing prevalence of cancer, technological advancement in cancer diagnostics & healthcare infrastructure, and an increasing demand for early detection and classification of cancer.
In addition, rising adoption of precision medicine is drives market growth further. The increasing incidence of cancer globally has led to a growing dependence on AI in the field of oncology. According to the NIH estimates of 2023, approximately 2.0 million individuals in the U.S. are diagnosed with cancer. Breast cancer was the most diagnosed cancer, with an estimated 297,790 cases in women and 2,800 cases in men. Among men, prostate cancer was the most frequently diagnosed cancer, and overall, it was the second most common diagnosis, with an anticipated 288,300 cases. The estimated number of new cases of lung and bronchus cancer made it the third most diagnosed cancer.
The growing initiatives undertaken by public and private organizations to invest in research and development (R&D) for introduction of novel technologies are further anticipated to fuel growth of the market. For instance, in October 2022, Tempus, a company specializing in precision medicine and AI, recently announced a program called Tempus+. This proprietary program utilizes real-world data to power collaborative precision oncology research. A community of researchers, including Baylor College of Medicine, Allegheny Health Network, Stanford Cancer Center, Rush University Medical Center, TriHealth, and others, is already using the Tempus+ program to advance their research. Furthermore, increasing product approval of AI-associated medical devices is anticipated to boost market growth. In January 2024, the U.S. FDA approved the first AI medical device, DermaSensor, to detect skin cancer.
The future of AI applications in cancer care is poised for groundbreaking advancements, encompassing early detection, precision medicine, and personalized treatment plans. AI's ability to analyze vast datasets, identify subtle patterns, and provide real-time insights holds the potential to revolutionize cancer diagnosis and therapy, ushering in a new era of improved patient outcomes and more efficient healthcare delivery.
Global AI In Oncology Market Report Segmentation
This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global AI in oncology market report based on component type, cancer type, application, end use, and region:
- Component Type Outlook (Revenue, USD Million, 2021 - 2033)
- Software Solutions
- Hardware
- Services
- Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Brain Tumor
- Others
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Diagnostics (Pathology, Cancer Radiology)
- Radiation therapy (Radiotherapy)
- Research & Development (Drug design, development process, etc.)
- Chemotherapy
- Immunotherapy
- End Use Type Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Surgical Centers & Medical Institutes
- Others (Pharmaceutical companies, Research institutes & training centers)
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1 Market Segmentation and Scope
- 1.1.1 Segment scope
- 1.1.2 Regional scope
- 1.1.3 Estimates and forecast timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased database:
- 1.3.2 GVR's internal database
- 1.3.3 Secondary sources
- 1.3.4 Primary research
- 1.3.5 Details of primary research
- 1.4 Information or Data Analysis
- 1.4.1 Data analysis models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis
- 1.6.1.1 Approach: Commodity Flow Approach
- 1.7 Research Assumptions
- 1.8 List of Secondary Sources
- 1.9 List of Abbreviations
Chapter 2. Executive Summary
- 2.1 Market Outlook
- 2.2 Segment Outlook
- 2.3 Competitive Insights
Chapter 3. AI In Oncology Market Variables, Trends, & Scope
- 3.1 Market Lineage Outlook
- 3.1.1 Parent market sanalysis
- 3.2 Market Dynamics
- 3.2.1 Market drivers analysis
- 3.2.2 Market restraint analysis
- 3.2.3 Market opportunity analysis
- 3.2.4 Market challenges analysis
- 3.3 AI In Oncology: Market Analysis Tools
- 3.3.1 Industry analysis - Porter's Five Forces Analysis
- 3.3.2 PESTLE analysis
- 3.4 Case studies
Chapter 4. AI In Oncology Market Segment Analysis, By Component Type, 2021 - 2033 (USD Million)
- 4.1 Definition and Scope
- 4.2 Component Type Market Share Analysis, 2025 & 2033
- 4.3 Segment Dashboard
- 4.4 Global AI In Oncology Market, by Component, 2021 to 2033
- 4.5 Software Solutions
- 4.5.1 Software solutions market estimates and forecast, 2021 - 2033 (USD Million)
- 4.6 Hardware
- 4.6.1 Hardware market estimates and forecast, 2021 - 2033 (USD Million)
- 4.7 Services
- 4.7.1 Services market estimates and forecast, 2021 - 2033 (USD Million)
Chapter 5. AI In Oncology Market Segment Analysis, By Cancer Type, 2021 - 2033 (USD Million)
- 5.1 Definition and Scope
- 5.2 Cancer Type Market Share Analysis, 2025 & 2033
- 5.3 Segment Dashboard
- 5.4 Global AI In Oncology Market, by Cancer Type, 2021 to 2033
- 5.5 Breast Cancer
- 5.5.1 Breast cancer market estimates and forecast, 2021 - 2033 (USD Million)
- 5.6 Lung Cancer
- 5.6.1 Lung cancer market estimates and forecast, 2021 - 2033 (USD Million)
- 5.7 Prostate Cancer
- 5.7.1 Prostate cancer market estimates and forecast, 2021 - 2033 (USD Million)
- 5.8 Colorectal Cancer
- 5.8.1 Colorectal cancer market estimates and forecast, 2021 - 2033 (USD Million)
- 5.9 Brain Tumor
- 5.9.1 Brain tumor market estimates and forecast, 2021 - 2033 (USD Million)
- 5.10 Others
- 5.10.1 Others market estimates and forecast, 2021 - 2033 (USD Million)
Chapter 6. AI In Oncology Market Segment Analysis, By Application, 2021 - 2033 (USD Million)
- 6.1 Definition and Scope
- 6.2 Application Market Share Analysis, 2025 & 2033
- 6.3 Segment Dashboard
- 6.4 Global AI In Oncology Market, by Application, 2021 to 2033
- 6.5 Diagnostics (Pathology, Cancer Radiology)
- 6.5.1 Diagnostics (pathology, cancer radiology) market estimates and forecast, 2021 - 2033 (USD Million)
- 6.6 Radiation Therapy (Radiotherapy)
- 6.6.1 Radiation therapy (radiotherapy) market estimates and forecast, 2021 - 2033 (USD Million)
- 6.7 Research & Development (Drug Design, Development Process, etc.)
- 6.7.1 Research & development (drug design, development process, etc.) market estimates and forecast, 2021 - 2033 (USD Million)
- 6.8 Chemotherapy
- 6.8.1 Chemotherapy market estimates and forecast, 2021 - 2033 (USD Million)
- 6.9 Immunotherapy
- 6.8.1 Immunotherapy market estimates and forecast, 2021 - 2033 (USD Million)
Chapter 7. AI In Oncology Market Segment Analysis, By End Use Type, 2021 - 2033 (USD Million)
- 7.1 Definition and Scope
- 7.2 Application Market Share Analysis, 2025 & 2033
- 7.3 Segment Dashboard
- 7.4 Global AI In Oncology Market, by Application, 2021 to 2033
- 7.5 Hospitals
- 7.5.1 Hospitals market estimates and forecast, 2021 - 2033 (USD Million)
- 7.6 Surgical Centers & Medical Institutes
- 7.6.1 Surgical centers & medical institutes market estimates and forecast, 2021 - 2033 (USD Million)
- 7.7 Others (Pharmaceutical Companies, Research Institutes & Training Centers)
- 7.7.1 Others (pharmaceutical companies, research institutes & training centers) market estimates and forecast, 2021 - 2033 (USD Million)
Chapter 8. AI In Oncology Market Segment Analysis, By Region, By Component, By Cancer Type, By Application, By End-use, 2021 - 2033 (USD Million)
- 8.1. Definition & Scope
- 8.2. Regional Market Share Analysis, 2025 & 2033
- 8.3. Regional Market Dashboard
- 8.4. Regional Market Snapshot
- 8.5. SWOT Analysis
- 8.6. North America
- 8.6.1. North America Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.6.2. U.S.
- 8.6.2.1. Key Country Dynamic
- 8.6.2.2. Regulatory Framework
- 8.6.2.3. Competitive Insights
- 8.6.2.4. U.S. Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.6.3. Canada
- 8.6.3.1. Key Country Dynamic
- 8.6.3.2. Regulatory Framework
- 8.6.3.3. Competitive Insights
- 8.6.3.4. Canada Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7. Europe
- 8.7.1. Europe Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.2. Germany
- 8.7.2.1. Key Country Dynamic
- 8.7.2.2. Regulatory Framework
- 8.7.2.3. Competitive Insights
- 8.7.2.4. Germany Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.3. UK
- 8.7.3.1. Key Country Dynamic
- 8.7.3.2. Regulatory Framework
- 8.7.3.3. Competitive Insights
- 8.7.3.4. UK Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.4. France
- 8.7.4.1. Key Country Dynamic
- 8.7.4.2. Regulatory Framework
- 8.7.4.3. Competitive Insights
- 8.7.4.4. France Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.5. Italy
- 8.7.5.1. Key Country Dynamic
- 8.7.5.2. Regulatory Framework
- 8.7.5.3. Competitive Insights
- 8.7.5.4. Italy Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.6. Spain
- 8.7.6.1. Key Country Dynamic
- 8.7.6.2. Regulatory Framework
- 8.7.6.3. Competitive Insights
- 8.7.6.4. Spain Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.7. Denmark
- 8.7.7.1. Key Country Dynamic
- 8.7.7.2. Regulatory Framework
- 8.7.7.3. Competitive Insights
- 8.7.7.4. Denmark Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.8. Sweden
- 8.7.8.1. Key Country Dynamic
- 8.7.8.2. Regulatory Framework
- 8.7.8.3. Competitive Insights
- 8.7.8.4. Sweden Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.9. Norway
- 8.7.9.1. Key Country Dynamic
- 8.7.9.2. Regulatory Framework
- 8.7.9.3. Competitive Insights
- 8.7.9.4. Norway Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.8. Asia Pacific
- 8.8.1. Asia Pacific Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.8.2. Japan
- 8.8.2.1. Key Country Dynamic
- 8.8.2.2. Regulatory Framework
- 8.8.2.3. Competitive Insights
- 8.8.2.4. Japan Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.8.3. China
- 8.8.3.1. Key Country Dynamic
- 8.8.3.2. Regulatory Framework
- 8.8.3.3. Competitive Insights
- 8.8.3.4. China Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.8.4. India
- 8.8.4.1. Key Country Dynamic
- 8.8.4.2. Regulatory Framework
- 8.8.4.3. Competitive Insights
- 8.8.4.4. India Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.8.5. South Korea
- 8.8.5.1. Key Country Dynamic
- 8.8.5.2. Regulatory Framework
- 8.8.5.3. Competitive Insights
- 8.8.5.4. South Korea Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.8.6. Australia
- 8.8.6.1. Key Country Dynamic
- 8.8.6.2. Regulatory Framework
- 8.8.6.3. Competitive Insights
- 8.8.6.4. Australia Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.8.7. Thailand
- 8.8.7.1. Key Country Dynamic
- 8.8.7.2. Regulatory Framework
- 8.8.7.3. Competitive Insights
- 8.8.7.4. Thailand Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.9. Latin America
- 8.9.1. Latin America Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.9.2. Brazil
- 8.9.2.1. Key Country Dynamic
- 8.9.2.2. Regulatory Framework
- 8.9.2.3. Competitive Insights
- 8.9.2.4. Brazil Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.9.3. Mexico
- 8.9.3.1. Key Country Dynamic
- 8.9.3.2. Regulatory Framework
- 8.9.3.3. Competitive Insights
- 8.9.3.4. Mexico Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.9.4. Argentina
- 8.9.4.1. Key Country Dynamic
- 8.9.4.2. Regulatory Framework
- 8.9.4.3. Competitive Insights
- 8.9.4.4. Argentina Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.10. MEA
- 8.10.1. MEA Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.10.2. South Africa
- 8.10.2.1. Key Country Dynamic
- 8.10.2.2. Regulatory Framework
- 8.10.2.3. Competitive Insights
- 8.10.2.4. South Africa Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.10.3. Saudi Arabia
- 8.10.3.1. Key Country Dynamic
- 8.10.3.2. Regulatory Framework
- 8.10.3.3. Competitive Insights
- 8.10.3.4. Saudi Arabia Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.10.4. UAE
- 8.10.4.1. Key Country Dynamic
- 8.10.4.2. Regulatory Framework
- 8.10.4.3. Competitive Insights
- 8.10.4.4. UAE Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.10.5. Kuwait
- 8.10.5.1. Key Country Dynamic
- 8.10.5.2. Regulatory Framework
- 8.10.5.3. Competitive Insights
- 8.10.5.4. Kuwait Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
Chapter 9. AI In Oncology Market - Competitive Analysis
- 9.1. Recent Developments & Impact Analysis, by Key Market Participants
- 9.2. Company Categorization
- 9.3. Company Profiles
- 9.3.1. Azra AI
- 9.3.1.1. Overview
- 9.3.1.2. Financial Performance
- 9.3.1.3. Service Benchmarking
- 9.3.1.4. Strategic Initiatives
- 9.3.2. ICAD, INC.
- 9.3.2.1. Overview
- 9.3.2.2. Financial Performance
- 9.3.2.3. Service Benchmarking
- 9.3.2.4. Strategic Initiatives
- 9.3.3. Siemens Healthcare GmbH
- 9.3.3.1. Overview
- 9.3.3.2. Financial Performance
- 9.3.3.3. Service Benchmarking
- 9.3.3.4. Strategic Initiatives
- 9.3.4. Intel Corporation
- 9.3.4.1. Overview
- 9.3.4.2. Financial Performance
- 9.3.4.3. Service Benchmarking
- 9.3.4.4. Strategic Initiatives
- 9.3.5. GE HealthCare
- 9.3.5.1. Overview
- 9.3.5.2. Financial Performance
- 9.3.5.3. Service Benchmarking
- 9.3.5.4. Strategic Initiatives
- 9.3.6. NVIDIA Corporation
- 9.3.6.1. Overview
- 9.3.6.2. Financial Performance
- 9.3.6.3. Service Benchmarking
- 9.3.6.4. Strategic Initiatives
- 9.3.7. Digital Diagnostics Inc.
- 9.3.7.1. Overview
- 9.3.7.2. Financial Performance
- 9.3.7.3. Service Benchmarking
- 9.3.7.4. Strategic Initiatives
- 9.3.8. ConcertAI
- 9.3.8.1. Overview
- 9.3.8.2. Financial Performance
- 9.3.8.3. Service Benchmarking
- 9.3.8.4. Strategic Initiatives
- 9.3.9. Median Technologies
- 9.3.9.1. Overview
- 9.3.9.2. Financial Performance
- 9.3.9.3. Service Benchmarking
- 9.3.9.4. Strategic Initiatives
- 9.3.10. PathAI
- 9.3.10.1. Overview
- 9.3.10.2. Financial Performance
- 9.3.10.3. Service Benchmarking
- 9.3.10.4. Strategic Initiatives
- 9.3.11. MVision AI
- 9.3.11.1. Overview
- 9.3.11.2. Financial Performance
- 9.3.11.3. Service Benchmarking
- 9.3.11.4. Strategic Initiatives